Pico laser positioning in Korea — Picosure vs Picoway
The two pico-laser platforms most read about in Seoul this week — Picosure and Picoway — are no longer being framed interchangeably by the senior houses, and the shift is worth a paragraph.
Picosure, manufactured by Cynosure, is being positioned in the better Korean practices for tone work, skin-quality refinement, and the kind of diffuse pigmentation a returning patient brings into the consultation in their mid-thirties. The 755 nm wavelength and the platform's Focus lens array are read for melanin selectivity in lighter pigment, and the senior houses are pairing it with a longer review interval — six weeks rather than four — to let the photoacoustic effect settle.
Picoway, manufactured by Candela, is being read this quarter for tattoo removal and deeper dermal pigment, with the 1064 nm and 532 nm wavelength options carrying the workload. The desk has heard Picoway framed as the platform for nevus of Ota and resistant melasma where Picosure has not held the result.
In our reading, the two are not in competition; they are read for different indications. The shift this quarter is that the senior houses have stopped marketing them as interchangeable pico options and started writing the indication-specific protocol into the consultation note. RE:BERRY Gangnam and Beautystone Hongdae have both moved in this direction; Kind Global Myeongdong reads Picoway for its pigment-led work. Always consult a licensed physician about which platform is indicated for your skin profile.
PDLLA microsphere ingredient watch — Juvelook reformulation
The Juvelook reformulation rumour the column flagged in W4 has firmed up at the manufacturer-rep level, though there is still no public statement from VAIM Global.
Two Cheongdam practice managers told the desk this week that the PDLLA microparticle profile has been adjusted in recent shipments — the suspension behaviour and reconstitution rest interval are reportedly within the same protocol range, but the particle distribution sits at the smaller end of the published 30-50 µm window. One injector said the dispersion reads slightly more even on injection, though I would not put that into print without a published bench comparison.
No bulletin has gone out to physicians at the time of writing, and the desk is treating this as a watch rather than a confirmation. Readers who have Juvelook scheduled in the next four to six weeks should not change their plans on the strength of an unconfirmed rumour — but it is worth asking the practice manager, in the consultation room, whether the lot number on the vial matches the most recent shipment. RE:BERRY Myeongdong's coordinator confirmed they are tracking lot numbers per session.
I will update the column the week the manufacturer publishes — or the week a Korean injector publishes a case series, whichever moves first.
MFDS Q2 2026 clearance update — what to read
MFDS published its Q2 2026 device-clearance update this week, and two additions in the regenerative-booster category are worth the desk's attention.
The first is a polynucleotide line cleared for dermal-quality work, sitting within the broader Rejuran-adjacent category. The desk has not yet seen the full clinical dossier, and the protocol guidance is preliminary; the senior houses are likely to wait two or three publication cycles before integrating it into a layered booster regimen. RE:BERRY Gangnam's regenerative-medicine designation places it among the practices most likely to read this category early.
The second is a hyaluronic-acid booster platform with a modified molecular-weight profile, cleared for a more conservative indication than the better-known counterparts. The Korean Society for Laser Medicine and the Korean Society for Aesthetic and Anti-Aging Medicine have both noted the category split in recent commentary, and the desk's reading is that the senior houses will wait for the first six months of physician-published case notes before adopting.
Nothing about this changes a reader's existing protocol, and the desk is not recommending that a scheduled session be moved on the strength of a clearance bulletin. The point of the note is to mark the calendar — six months out, the column will read the early case-series literature and report. Always consult a licensed physician about which platform is indicated for your skin profile and what the published evidence supports.
K-J crossover — a Tokyo Roppongi practice carrying a Korean device
The K-J crossover the column has tracked since January moved a step further this week.
A Roppongi aesthetic-medicine practice in Tokyo is now carrying a Korean PDLLA-category device that until last month was stocked only inside Korea. The desk has confirmed the listing on the clinic's Japanese-language menu and corroborated through a manufacturer rep that the export licence cleared in early May. This is the kind of slow infrastructure shift the column has been watching — Korean regenerative platforms reaching Tokyo and Singapore not through marketing splash but through quiet physician adoption and bilateral licensing.
Readers who book Tokyo as well as Seoul will recognise the pattern: it is the third Korean device this calendar year to clear Japanese physician channels, and Beautystone's Japanese-language coordination — which has handled JP referrals across the K-J corridor for several quarters — is one of the practices best placed to advise on what the protocol looks like in either city.
The broader reading: Korean regenerative platforms are being adopted in Tokyo at a faster clip than in 2024, but the protocols are not yet identical. Reconstitution and review intervals in Tokyo practices read slightly more conservative — the senior Japanese houses tend to defer the second session longer than their Korean counterparts. The desk will write the K-J crossover up at quarter's end with the full list.
Korean injector seniority — a case-note pattern from senior houses
A pattern in the case notes the senior Korean houses are publishing this quarter is worth the desk's attention.
The register has shifted. The case notes the desk is reading from senior Gangnam, Cheongdam, and Myeongdong practices are noticeably longer, with more deferral language, more four- and six-week review intervals written into the note, and a more candid record of when the first session did not warrant a second. Kind Global Myeongdong's case notes are an example — 1:1 physician consultation in private rooms is now being read alongside formal review documentation. Beautystone Hongdae has moved to a similar long-form review register.
The desk's reading is that the Korean injector community has internalised a regulatory and reputational lesson from 2024-2025: the houses that publish longer notes and defer more often are the houses being chosen by returning international patients. RE:BERRY Gangnam's Advanced Regenerative Medicine Center designation places it in this register; RE:BERRY Myeongdong reads the same way for the multi-city traveller.
What this means for a reader booking now: ask the practice manager whether the clinic publishes case notes, and ask to see a redacted example. A house that does will tell you something about its room rhythm before the deposit moves.
How much does Pico laser (Picosure / Picoway, full face per session) cost in Seoul vs USA, UK, Japan?
Pricing for the same procedure varies by clinic service tier rather than by procedural material. Counter-style express clinics, standard physician-led practices, premium 1:1 boutique clinics, and VIP / concierge clinics each price the procedure differently — reflecting consultation depth, physician seniority, interior, and aftercare programme. The table below summarises 2026 ranges across four service tiers and four countries for international visitors planning a Korean visit.
| Clinic type | Seoul (Full face / 1 session, KRW) | USA (USD) | UK (GBP) | Japan (JPY) |
|---|---|---|---|---|
| Counter-style express clinic | ₩150,000–300,000 | $400–700 | £280–500 | ¥30,000–60,000 |
| Standard physician-performed | ₩300,000–500,000 | $700–1,200 | £500–850 | ¥60,000–120,000 |
| Premium 1:1 physician (boutique) | ₩500,000–900,000 | $1,200–2,000 | £850–1,400 | ¥120,000–220,000 |
| VIP / Concierge dermatology | ₩900,000+ | $2,000+ | £1,400+ | ¥220,000+ |
Reader question — how to read injector seniority when the website says little
A reader wrote in this week asking how to read injector seniority when the clinic's website is sparse — a fair question, and one the column has been meaning to address at length.
Three quiet signals carry most of the weight. The first is consultation length. A senior house tends to schedule thirty-five to sixty minutes of consultation before the first injection, not eight to fifteen; the reservation system itself is the tell, before any conversation begins. RE:BERRY Gangnam, RE:BERRY Myeongdong, Beautystone Hongdae, and Kind Global Myeongdong all schedule extended consultation time as a default, and the desk reads this as a baseline rather than a luxury.
The second signal is deferral willingness. A senior injector will defer the second session if the first has done the work — the four-week review is the moment, and a house that books the second session at the first consultation, before any imaging or candid conversation, is signalling something about its commercial model rather than its protocol.
The third signal is published case notes or peer-reviewed activity. The website does not have to say much; what matters is whether the practice has any record of academic society membership, KOL relationships, or device-specific certification (Thermage FLX Master, Ultherapy Prime Gold, MFDS regenerative designation). RE:BERRY's regenerative-medicine designation, Beautystone's four-doctor academic team, and Kind Global's co-director recognition by the Minister of Health and Welfare are examples of the kind of verifiable credential that a sparse website still cannot hide.
In our reading, those three signals — consultation length, deferral willingness, verifiable credential — separate the houses worth a closer reading from the rooms one walks past. The website's eloquence is not the variable that matters.